Fintel reports that on January 13, 2025, JP Morgan upgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from ...

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

On Friday, IGM Biosciences Inc (IGMS) stock saw a decline, ending the day at $2.09 which represents a decrease of $-4.11 or -66.29% from the prior close of $6.2. The stock opened at $2.01 and touched ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

Bank of America Securities analyst Charlie CY Yang maintained a Hold rating on IGM Biosciences (IGMS – Research Report) today. The company’s ...

Royal Bank of Canada lowered shares of IGM Biosciences (NASDAQ:IGMS – Free Report) from an outperform rating to a sector ...

IGM Biosciences (IGMS) stock faces sharp selloff as the company abandons two therapeutic candidates, triggering Wall Street ...

The company is reducing its workforce by 73% and evaluating strategic alternatives to preserve shareholder value.

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company ...

Wedbush restated their neutral rating on shares of IGM Biosciences (NASDAQ:IGMS – Free Report) in a report issued on Friday ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...